2026-04-17T04:21:37Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4587142025-07-29T19:50:47Zcom_2072_98col_2072_378192

urn:hdl:2072/458714 Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic Grau, Santiago Echeverría-Esnal, Daniel Gómez-Zorrilla, Silvia Navarrete-Rouco, Maria Eugenia Masclans, Joan R Espona, Merce Gracia-Arnillas, Maria Pilar Duran-Jordà, Xavier Comas Serrano, Mercè Horcajada, Juan Pablo Ferrández, Olivia Antimicrobial stewardship COVID-19 Defined daily doses (DDD) Antimicrobial resistance Antibiotic consumption Background: The first wave of COVID-19 pandemic may have significantly impacted antimicrobial consumption in hospitals. The objective of this study was to assess the evolution of antimicrobial consumption during this period. Methods : A retrospective quasi-experimental before-after study was conducted in a Spanish tertiary care hospital. The study compared two periods: pre-pandemic, from January 2018 to February 2020, and during the COVID-19 pandemic from March to June 2020. Antimicrobial consumption was analyzed monthly as defined daily doses (DDD)/100 bed-days and overall hospital and ICU consumption were evaluated. Results: An increase in the hospital consumption was noticed. Although only ceftaroline achieved statistical significance (p = 0.014), a rise was observed in most of the studied antimicrobials. A clear temporal pattern was detected. While an increase in ceftriaxone and azithromycin was observed during March, an increment in the consumption of daptomycin, carbapenems, linezolid, ceftaroline, novel cephalosporin/β-lactamase inhibitors or triazoles during April-May was noticed. In the ICU, these findings were more evident, namely ceftriaxone (p = 0.029), carbapenems (p = 0.002), daptomycin (p = 0.002), azithromycin (p = 0.030), and linezolid (p = 0.011) but followed a similar temporal pattern. Conclusion : An increase in the antimicrobial consumption during the first wave of COVID-19 pandemic was noticed, especially in the ICU. Availability of updated protocols and antimicrobial stewardship programs are essential to optimize these outcomes. 2021 Article Antibiotics ; Vol. 10 (january 2021) open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/